Cargando…
Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model.
The matrix metalloproteinase inhibitor batimastat was administered to a human colorectal cancer ascites model, which was initiated by injection of C170HM2 cells into the peritoneal cavity of SCID mice and resulted in solid tumour deposits and ascites formation. The cell line expressed both the 72 an...
Autores principales: | Watson, S. A., Morris, T. M., Parsons, S. L., Steele, R. J., Brown, P. D. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074768/ https://www.ncbi.nlm.nih.gov/pubmed/8912529 |
Ejemplares similares
-
The Behavior of Matrix Metalloproteinases and Their Inhibitors in Colorectal Cancer
por: Herszényi, László, et al.
Publicado: (2012) -
Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissuenhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase
por: Collins, H M, et al.
Publicado: (2001) -
The Role of Matrix Metalloproteinases in Colorectal Cancer
por: Said, Anan H., et al.
Publicado: (2014) -
Production of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Human Breast Carcinomas
por: Iwata, Hiroji, et al.
Publicado: (1996) -
Repurposing Cancer Drugs Batimastat and Marimastat to Inhibit the Activity of a Group I Metalloprotease from the Venom of the Western Diamondback Rattlesnake, Crotalus atrox
por: Layfield, Harry J., et al.
Publicado: (2020)